/UPDATE -- Nektar Therapeutics/

ConferencepositiveRezpegaldesleukinPositive

AI Analysis

Summary

Nektar Therapeutics presented new long-term durability and disease improvement data for Rezpegaldesleukin in patients with alopecia areata and atopic dermatitis at EADV Congress 2026.

Outcome Details

Long-term durability and disease improvement data presented

Importance:5/10

Sentiment:

0.60

Nektar TherapeuticsRezpegaldesleukinAlopecia AreataAtopic DermatitisEADV Congress 2026Clinical Data

Related Companies

$NKTR

Read the original article

Published by PR Newswire Pharma on October 1, 2026 12:40 PM

Read Original